Data-quality flags on Nicaragua
% of people on ART who are virally suppressed (third 95), Chinandega, 2019 (PEPFAR results by province). The ratio of 200 people reported as virally suppressed to a denominator of 199 is 100.5 per cent, above 100 per cent, so the numerator and the denominator do not come from the same group of patients for Chinandega in 2019.
HIV tests performed with the result returned to the person, 2023 (PEPFAR Panorama Spotlight). The value moved from 6,066 in 2022 to 38,654 in 2023, a change of more than threefold in a single year. The move from 6,066 to 38,654 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
Number of people on ART (PEPFAR MER TX_CURR), 2019 (PEPFAR Panorama Spotlight). The value moved from 353 in 2018 to 1,747 in 2019, a change of more than threefold in a single year. The move from 353 to 1,747 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2018 and 2019 are not comparable. Check the figures by reporting organisation before reading a trend across 2018 and 2019.
People who completed a course of TB preventive therapy, 2023 (PEPFAR Panorama Spotlight). The value moved from 3,719 in 2022 to 833 in 2023, a change of more than threefold in a single year. The move from 3,719 to 833 is likely to reflect a change in which organisations funded by PEPFAR report the figures, or in the scope of the PEPFAR reporting, so the values for 2022 and 2023 are not comparable. Check the figures by reporting organisation before reading a trend across 2022 and 2023.
Sources of the figures for Nicaragua
| Source | Type | Rows | Indicators | Years | Read from | Retrieved |
|---|---|---|---|---|---|---|
| PEPFAR results by province | Programme record | 192 | 6 | 2016–2025 | data.pepfar.gov | 2026-10-12 |
| UNAIDS AIDSinfo | Programme record | 153 | 17 | 2000–2024 | aidsinfo.unaids.org | 2026-10-20 |
| WHO Global Tuberculosis Programme | Programme record | 134 | 16 | 2000–2024 | extranet.who.int | 2026-10-16 |
| Global Fund Data Service | Programme record | 75 | 7 | 2017–2025 | fetch.theglobalfund.org | 2026-10-12 |
| ForeignAssistance.gov | Expenditure account | 70 | 4 | 2003–2026 | foreignassistance.gov | 2026-10-29 |
| OECD Creditor Reporting System | Expenditure account | 66 | 3 | 2002–2024 | sdmx.oecd.org | 2026-10-12 |
| IATI, through d-portal | Expenditure account | 62 | 3 | 2000–2026 | d-portal.org | 2026-10-12 |
| PEPFAR Panorama Spotlight | Programme record | 48 | 8 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR testing by modality | Programme record | 46 | 6 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| PAHO Interactive HIV Data Dashboard | Programme record | 38 | 2 | 2010–2024 | paho.org | 2026-10-14 |
| WHO HIV testing services dashboard | Programme record | 38 | 4 | 2018–2024 | eic-database-290813.ew.r.appspot.com | 2026-10-14 |
| PEPFAR results by funding agency | Programme record | 30 | 5 | 2018–2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR budgets and expenditure | Expenditure account | 30 | 6 | 2021–2025 | data.pepfar.gov | 2026-10-12 |
| World Bank Open Data | Modelled estimate | 26 | 1 | 2000–2025 | api.worldbank.org | 2026-10-12 |
| WHO Global Health Observatory | Programme record | 18 | 2 | 2022–2024 | ghoapi.azureedge.net | 2026-10-12 |
| PAHO Core Indicators | Programme record | 16 | 1 | 2010–2025 | opendata.paho.org | 2026-10-13 |
| Demographic and Health Surveys | Survey | 14 | 1 | 2001 | api.dhsprogram.com | 2026-10-16 |
| Nicaragua Ministry of Health health map (Mapa Nacional de la Salud) | Programme record | 7 | 1 | 2017–2023 | mapasalud.minsa.gob.ni | 2026-10-27 |
| Global Fund allocations | Expenditure account | 4 | 1 | 2017–2026 | fetch.theglobalfund.org | 2026-10-12 |
| PEPFAR commodity procurement plans | Expenditure account | 4 | 4 | 2021 | data.pepfar.gov | 2026-10-12 |
| PEPFAR human resources for health inventory | Expenditure account | 3 | 3 | 2025 | data.pepfar.gov | 2026-10-12 |
| PEPFAR operating-unit budgets | Expenditure account | 2 | 2 | 2020 | data.pepfar.gov | 2026-10-12 |
Indicators held
| Indicator | Domain | Unit | Rows | Years | Sources | Most recent value |
|---|---|---|---|---|---|---|
| Actual expenditure on collaborative TB/HIV activities | Financing | USD | 3 | 2018–2023 | WHO Global Tuberculosis Programme | $224k (2023) |
| Budget required for collaborative TB/HIV activities | Financing | USD | 4 | 2018–2024 | WHO Global Tuberculosis Programme | $66k (2024) |
| Domestic funding received by the national TB programme | Financing | USD | 3 | 2018–2023 | WHO Global Tuberculosis Programme | $5.0m (2023) |
| Expected Global Fund funding for the national TB programme | Financing | USD | 4 | 2018–2024 | WHO Global Tuberculosis Programme | $3.9m (2024) |
| Expected USAID funding for the national TB programme | Financing | USD | 3 | 2018–2020 | WHO Global Tuberculosis Programme | $0 (2020) |
| Expected domestic funding for the national TB programme | Financing | USD | 4 | 2018–2024 | WHO Global Tuberculosis Programme | $5.5m (2024) |
| Expected funding for collaborative TB/HIV activities | Financing | USD | 4 | 2018–2024 | WHO Global Tuberculosis Programme | $60k (2024) |
| External HIV financing (all donors, ODA) | Financing | USD | 23 | 2002–2024 | OECD Creditor Reporting System | $6.7m (2024) |
| External HIV financing from governments other than the United States (IATI) | Financing | USD | 25 | 2000–2025 | IATI, through d-portal | $0 (2025) |
| External HIV financing from multilateral bodies other than the Global Fund (IATI) | Financing | USD | 13 | 2012–2026 | IATI, through d-portal | $46k (2026) |
| External HIV financing from the United States (ODA) | Financing | USD | 44 | 2003–2026 | ForeignAssistance.gov, OECD Creditor Reporting System | $514k (2026) |
| Funding received for collaborative TB/HIV activities | Financing | USD | 3 | 2018–2023 | WHO Global Tuberculosis Programme | $247k (2023) |
| Global Fund HIV allocation for a whole three-year cycle, not an annual figure | Financing | USD per three-year allocation cycle | 4 | 2017–2026 | Global Fund allocations | 8,170,207 (2026) |
| Global Fund HIV disbursements to the country | Financing | USD | 46 | 2003–2026 | IATI, through d-portal, OECD Creditor Reporting System | $1.8m (2026) |
| Global Fund funding received by the national TB programme | Financing | USD | 3 | 2018–2023 | WHO Global Tuberculosis Programme | $2.1m (2023) |
| PEPFAR expenditure, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $916k (2025) |
| PEPFAR expenditure, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $0 (2025) |
| PEPFAR expenditure, all US agencies | Financing | USD | 6 | 2020–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets | $916k (2025) |
| PEPFAR planned commodity procurement, like for like | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $10k (2021) |
| PEPFAR planned funding (budget), all US agencies | Financing | USD | 6 | 2020–2025 | PEPFAR budgets and expenditure, PEPFAR operating-unit budgets | $2.2m (2025) |
| PEPFAR planned funding, HHS/CDC | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $1.8m (2025) |
| PEPFAR planned funding, USAID | Financing | USD | 5 | 2021–2025 | PEPFAR budgets and expenditure | $402k (2025) |
| PEPFAR planned procurement of antiretroviral drugs | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $0 (2021) |
| PEPFAR planned procurement of laboratory commodities | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $6k (2021) |
| PEPFAR planned procurement of rapid test kits | Financing | USD | 1 | 2021 | PEPFAR commodity procurement plans | $4k (2021) |
| PEPFAR spend on staff, human resources for health inventory | Financing | USD | 1 | 2025 | PEPFAR human resources for health inventory | $618k (2025) |
| PEPFAR-funded staff delivering services, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 8 (2025) |
| PEPFAR-funded staff, full-time equivalents | Financing | count | 1 | 2025 | PEPFAR human resources for health inventory | 17 (2025) |
| US HIV disbursements managed by Health and Human Services | Financing | USD | 16 | 2009–2026 | ForeignAssistance.gov | $514k (2026) |
| US HIV disbursements managed by USAID | Financing | USD | 23 | 2003–2026 | ForeignAssistance.gov | $0 (2026) |
| US HIV disbursements managed by other US agencies | Financing | USD | 8 | 2009–2016 | ForeignAssistance.gov | $0 (2016) |
| USAID funding received by the national TB programme | Financing | USD | 2 | 2018–2019 | WHO Global Tuberculosis Programme | $0 (2019) |
| % of PLHIV who have been diagnosed (first 95) | Treatment cascade | percent | 3 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| % of estimated HIV-positive incident TB cases on TB treatment and ART | Treatment cascade | percent | 19 | 2003–2023 | UNAIDS AIDSinfo | 72.3% (2023) |
| % of people living with HIV on ART who completed a course of TB preventive therapy | Treatment cascade | percent | 1 | 2023 | UNAIDS AIDSinfo | 76.3% (2023) |
| % of people newly enrolled in HIV treatment diagnosed with TB disease | Treatment cascade | percent | 12 | 2013–2024 | UNAIDS AIDSinfo | 8.5% (2024) |
| % of people newly enrolled in HIV treatment started on TB preventive therapy | Treatment cascade | percent | 11 | 2013–2024 | UNAIDS AIDSinfo | 61.5% (2024) |
| % of people on ART who are virally suppressed (third 95) | Treatment cascade | percent | 23 | 2019–2025 | PEPFAR results by province | Sub-national only, to 2025 |
| % of returned HIV test results that were positive | Treatment cascade | percent | 29 | 2018–2024 | UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 0.2% (2024) |
| HIV tests performed at a health facility | Treatment cascade | count | 13 | 2018–2025 | PEPFAR testing by modality, WHO HIV testing services dashboard | 49,892 (2025) |
| HIV tests performed through community outreach | Treatment cascade | count | 8 | 2018–2024 | PEPFAR testing by modality, WHO HIV testing services dashboard | 8,342 (2024) |
| HIV tests performed with the result returned to the person | Treatment cascade | count | 95 | 2016–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality, UNAIDS AIDSinfo, WHO Global Health Observatory, WHO HIV testing services dashboard | 49,892 (2025) |
| HIV-exposed infants tested within two months of birth | Treatment cascade | percent | 15 | 2010–2024 | UNAIDS AIDSinfo | 66.0% (2024) |
| HIV-positive TB patients started or continued on ART | Treatment cascade | count | 17 | 2015–2025 | Global Fund Data Service, WHO Global Tuberculosis Programme | 185 (2025) |
| Key-population people tested for HIV (count over the period) | Treatment cascade | count | 24 | 2018–2025 | Global Fund Data Service | By population group, sex or age only, to 2025 |
| New HIV diagnoses with a CD4 count below 200 | Treatment cascade | percent | 6 | 2015–2020 | UNAIDS AIDSinfo | 22.0% (2020) |
| Newly diagnosed at HHS/CDC-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 8 | 2018–2025 | PEPFAR results by funding agency | 178 (2025) |
| Newly diagnosed at USAID-funded partners (MER HTS_TST_POS) | Treatment cascade | count | 5 | 2020–2024 | PEPFAR results by funding agency | 238 (2024) |
| Newly enrolled on ART at HHS/CDC-funded partners (MER TX_NEW) | Treatment cascade | count | 8 | 2018–2025 | PEPFAR results by funding agency | 101 (2025) |
| Notified HIV cases, national case surveillance | Treatment cascade | count | 51 | 2010–2025 | Nicaragua Ministry of Health health map (Mapa Nacional de la Salud), PAHO Core Indicators, PAHO Interactive HIV Data Dashboard | 1,169 (2025) |
| Number newly diagnosed HIV-positive (PEPFAR MER HTS_TST_POS) | Treatment cascade | count | 54 | 2016–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province, PEPFAR testing by modality | 178 (2025) |
| Number of PLHIV virally suppressed (VL<1000) | Treatment cascade | count | 30 | 2019–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province | 4,326 (2025) |
| Number of people on ART (PEPFAR MER TX_CURR) | Treatment cascade | count | 50 | 2016–2025 | Global Fund Data Service, PEPFAR Panorama Spotlight, PEPFAR results by province | 5,980 (2025) |
| People living with HIV on ART who started TB preventive therapy | Treatment cascade | count | 4 | 2022–2025 | Global Fund Data Service | 750 (2025) |
| People newly diagnosed at a health facility | Treatment cascade | count | 8 | 2018–2025 | PEPFAR testing by modality | 178 (2025) |
| People newly diagnosed through community outreach | Treatment cascade | count | 7 | 2018–2024 | PEPFAR testing by modality | 298 (2024) |
| People newly enrolled on ART during the year | Treatment cascade | count | 52 | 2013–2025 | PEPFAR Panorama Spotlight, PEPFAR results by province, WHO Global Tuberculosis Programme | 101 (2025) |
| People on ART at HHS/CDC-funded partners (MER TX_CURR) | Treatment cascade | count | 8 | 2018–2025 | PEPFAR results by funding agency | 5,980 (2025) |
| People on ART at USAID-funded partners (MER TX_CURR) | Treatment cascade | count | 1 | 2020 | PEPFAR results by funding agency | 388 (2020) |
| People on ART on a dolutegravir-based regimen | Treatment cascade | percent | 10 | 2020–2024 | PAHO Interactive HIV Data Dashboard | By population group, sex or age only, to 2024 |
| People who completed a course of TB preventive therapy | Treatment cascade | count | 5 | 2018–2024 | PEPFAR Panorama Spotlight | 485 (2024) |
| Pregnant women tested for HIV in antenatal care | Treatment cascade | percent | 9 | 2015–2024 | UNAIDS AIDSinfo | 98.0% (2024) |
| TB patients recorded as HIV-positive | Treatment cascade | count | 15 | 2015–2024 | PEPFAR Panorama Spotlight, WHO Global Tuberculosis Programme | 2 (2024) |
| TB patients with an HIV test result recorded | Treatment cascade | count | 15 | 2015–2024 | PEPFAR Panorama Spotlight, WHO Global Tuberculosis Programme | 10 (2024) |
| Deaths from TB among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 58 (2024) |
| HIV prevalence among a key population | Epidemic estimates | percent | 5 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Incident TB cases among people living with HIV | Epidemic estimates | count | 50 | 2000–2024 | UNAIDS AIDSinfo, WHO Global Tuberculosis Programme | 200 (2024) |
| Condom use at last higher-risk sex (household survey) | Prevention and outreach | percent | 14 | 2001 | Demographic and Health Surveys | By population group, sex or age only, to 2001 |
| Key-population members reached by prevention programmes | Prevention and outreach | percent | 3 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Key-population people reached by outreach (count over the period) | Prevention and outreach | count | 24 | 2018–2025 | Global Fund Data Service | By population group, sex or age only, to 2025 |
| Male condoms distributed in a year | Prevention and outreach | count | 5 | 2019–2024 | UNAIDS AIDSinfo | 6,466,789 (2024) |
| People receiving PrEP | Prevention and outreach | count | 5 | 2023–2025 | Global Fund Data Service, UNAIDS AIDSinfo | 500 (2024) |
| Estimated size of a key population | Population denominators | count | 4 | 2024 | UNAIDS AIDSinfo | By population group, sex or age only, to 2024 |
| Total population | Population denominators | count | 26 | 2000–2025 | World Bank Open Data | 7,007,502 (2025) |
Every row shown on the Nicaragua page is in the panel download, with the source URL and the retrieval date of the row attached. See Data.
Turn your phone to read the chart upright